This kit is designed for the detection of binding activity between Human CTLA-4 and CD80, using a homogeneous AlphaLISA assay (no wash steps). This assay can facilitate the design and development of antibody therapetics by using competitive binding to CTLA-4/CD80.
true falseYou successfully added item(s) to your cart
For research use only. Not for use in diagnostic procedures.
Features:
AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a biotinylated CD80 binds to the Streptavidin-coated Alpha Donor beads, while His tagged CTLA-4 is captured by Anti-His AlphaLISA Acceptor beads. When CD80 binding to CTLA-4 happens, Donor beads and Acceptor beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
Human Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also known as CD152 (cluster of differentiation 152), is a cell membrane receptor and a member of immunoglobulin superfamily. CTLA-4 is expressed once a T cell becomes active and modulates T cell signals by blocking the CD80 (B7.1) and CD86 (B7.2) ligands from binding to CD28. CTLA-4, functioning as an immune checkpoint, downregulates T cell immune responses. Because of its profound inhibitory role blocking CTLA-4 and CD80 or CD86 binding has been considered as promising therapeutic target for human autoimmune disease and cancers.
Assay Target | CTLA4,CD80 |
---|---|
Assay Target Class | Protein |
Automation Compatible | Yes |
Detection Method | Alpha |
Product Brand Name | AlphaLISA |
Shipping Condition | Blue Ice |
Target Species | Human |
Therapeutic Area | Cancer |
Unit Size | 500 Assay Points |